SEIKAGAKU CORP.

In News

FDA slaps CRL on Seikagaku’s BLA for condoliase - The Pharma Letter

The Pharma Letter - Mar 14, 2025

Seikagaku’s Ferring-partnered condoliase for pain wins at adcom - BioWorld MedTech

BioWorld MedTech - Jan 10, 2025

Histological analysis of nucleus pulposus tissue from patients with lumbar disc herniation after condoliase administration - Wiley Online Library

Wiley Online Library - Apr 03, 2024

D-sorbitol can keep the viscosity of dispersive ophthalmic viscosurgical device at room temperature for long term - Nature

Nature - Nov 14, 2019

All Japanese osteoarthritis deal could total 12 billion yen - The Pharma Letter

The Pharma Letter - Jan 08, 2026

Eisai now gets rights to Seikagaku's osteoarthritis candidate SI-613 in South Korea - The Pharma Letter

The Pharma Letter - Sep 30, 2020

Ferring Pharma gains exclusive rights to Seikagaku’s condoliase - The Pharma Letter

The Pharma Letter - Aug 30, 2016

Manufacturing and marketing approval in Japan for Joyclu - The Pharma Letter

The Pharma Letter - Mar 25, 2021

Positive Phase III confirmatory study of ONO-5704/SI-613 in patients with knee osteoarthritis in Japan - The Pharma Letter

The Pharma Letter - Feb 19, 2019

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment